{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959961",
  "id": "02959961",
  "pages": 8,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwwvzvqfc8yn.pdf",
  "summary": "- **Clinical Results**: StemSmart\u2122 MSC therapy shows positive outcomes in steroid-refractory GVHD:  \n  - **Adults (Phase I trial)**: 58% complete response, 33% partial response; 55% 3-year survival vs. expected 15-20%.  \n  - **Children (compassionate use)**: All 10 survived to 12 months (vs. high expected mortality); 3 chronic GVHD patients alive >6 years post-treatment.  \n- **Market Opportunity**: GVHD treatment market projected to grow from $2.55bn (2023) to $5.31bn (2032).  \n- **Safety**: No infusion-related toxicities or serious adverse events reported.  \n- **Key Limitation**: No benefit observed in *newly diagnosed* GVHD (Phase II trial failed; early termination).  \n\n*No material capital markets/trading actions announced (e.g., no capital raising, M&A completion, or regulatory milestones).*",
  "usage": {
    "prompt_tokens": 5244,
    "completion_tokens": 204,
    "total_tokens": 5448,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T23:43:00.639239"
}